Avecho Biotechnology develops first generation TPM edible cannabinoid gummies

Avecho Biotechnology (ASX: AVE) has completed the development of a maiden batch of first generation TPM (tocopheryl phosphate mixture) gummies containing cannabinoids.

The company said the chewable, jelly-like product is uniquely positioned to address a range of therapeutic indications including pain, anxiety and sleep issues, as well as neurological and psychiatric disorders.

Made from a mixture of glycerin and gelatin, edible gummies are able to incorporate a range of medications or nutraceutical ingredients.

They have become an increasingly popular dosage form for use with cannabinoids, as they provide an alternative method of consumption to smoking and vaping without the associated respiratory issues.

Faster onset

Avecho chief executive officer Dr Paul Gavin said TPM gummies had outperformed standard products, demonstrating faster onset and greater magnitude of effect.

“The rapid onset has been particularly exciting as it demonstrates the ability of TPM to enhance buccal drug absorption, which is directly through the inside of the cheeks into the bloodstream… it avoids first pass metabolism where the drug is destroyed or converted during digestion,” he said.

“We have always suspected TPM had the appropriate chemistry to promote buccal absorption but have not previously worked with a dosage form appropriate for this route of administration.”

Absorption times

Cannabinoid absorption times from standard edible dosage forms can vary between 30 minutes to 1.5 hours during which time, patients can often eat more of the product in the belief that the first dose has not worked.

Consumption of multiple gummies can lead to a range of adverse effects once the accumulated amounts of THC (tetrahydrocannabinol) are absorbed.

Drug delivery system

TPM is Avecho’s proprietary drug delivery system derived from Vitamin E using unique and patented processes.

It has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho is developing TPM-enhanced injectable, oral and topical products for the human health market and to enhance the feed efficiency and health of livestock.

Dr Gavin said the company was in a “strong position” to enter discussions with local medicinal cannabis companies for the use of its gummy products in the Australian medicinal market.